SLC6A1 Connect published a study finding that approximately 15% of variability in developmental outcomes in SLC6A1 related disorder is explained by environmental and treatment-related factors rather than genetics alone.
Public source
Publisher name
Public post
For years, families affected by #SLC6A1 have asked one simple question: Can we change our child's future? A newly published study offers encouraging evidence that the an…
Company
SLC6A1 Connect
SLC6A1 Connect is a patient advocacy group dedicated to improving the lives of children and families affected by SLC6A1.
- Industry
- Research
- Location
- Frisco, US
- Company size
- 2–10 employees
About SLC6A1 Connect
SLC6A1 Connect is a research-focused patient advocacy group dedicated to accelerating the development of novel therapeutic approaches for children with SLC6A1-Related Disorder (SRD), a newly identified neuro-developmental disorder, by improving the lives of affected children and families. Our group is comprised of passionate and relentless mothers. Our mission is to advance scientific research through patient empowerment ultimately resulting in a disease modifying treatment.
See moreLatest activity
Latest activity from SLC6A1 Connect
3 signals
Products & Services
SLC6A1 Connect launched Merch Drop 2026 featuring new designs, friendship bracelets, beaded bag charms with a gold clasp, enamel brain pins, and tech tattoos.
Presence & Recognition
SLC6A1 Connect is helping researchers build a richer picture of SLC6A1 by uploading medical records to the Matrix platform.
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
Children's Tumor Foundation
Children's Tumor Foundation published a new recap and reference guide for the 2026 NF Data Workshop, including the NF Data Portal, NF Target Discovery Hub, NF Registry, and Lightning talk highlights.
Research & Knowledge
Foundation for Angelman Syndrome Therapeutics (FAST)
Foundation for Angelman Syndrome Therapeutics (FAST) published the Summer 2026 Angelman Syndrome Community Newsletter by Ultragenyx, which includes updates on investigational clinical trials, an Angelman Syndrome Caregiver Leadership Council meeting, and more.
Research & Knowledge
GeneDx
GeneDx published new research showing that hundreds of different genetic variants associated with autism may converge on a smaller number of shared biological pathways.
Research & Knowledge
International Rett Syndrome Foundation
International Rett Syndrome Foundation launched its new Clinical Trial Finder to bring together clinical trials and research studies relevant to Rett families from around the world.
Research & Knowledge
Rare Epilepsy Network (REN)